NCT06346067 2026-02-27
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
Erasca, Inc.
Phase 3 Active not recruiting
Erasca, Inc.
Taizhou Hanzhong biomedical co. LTD
Provectus Pharmaceuticals
Peking University Cancer Hospital & Institute
Merck Sharp & Dohme LLC
European Organisation for Research and Treatment of Cancer - EORTC
AstraZeneca